Ionis Pharmaceuticals (IONS) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is IONS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Ionis Pharmaceuticals NASDAQ: IONS remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more slowly than expected, CE…

TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential securities law violations on behalf of shareholder…

Ionis Pharmaceuticals, Inc. ( IONS ) UBS Global Biopharma Conference 2026 November 16, 2026 5:00 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Joon Lee - UBS Investment Ba…

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).…

Ionis cut its full-year TRYNGOLZA sales outlook by roughly half as third-quarter sales of the drug only achieved $9.3 million; IONS investors who lost money may have legal rights as an investigation gets underway Ionis c…

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA® (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), to …

IONS plunges as slower Tryngolza sales, reduced guidance and disappointing Wainua royalties rattle investors.…

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) traded down 7.3% during trading on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $58.00 to $41.00. The Goldman S…

Ionis topped third-quarter revenue estimates with roughly $243 million in sales, yet IONS shareholders took losses as the same report showed a $110 million net loss and a more than 50% cut to TRYNGOLZA guidance. NEW YORK…

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: UBS Global Biopharma Conference on M…

Ionis lowered 2026 TRYNGOLZA revenue guidance to approximately $50 million. DAWNZERA's third-quarter product sales rose 40% to $37 million.…

Ionis Pharmaceuticals, Inc. stock plunged over 25% after Q3 earnings, despite beating revenue and EPS expectations and reaffirming 2026 guidance. IONS slashed 2026 Tryngolza sales guidance by more than half due to slower…

Ionis told investors in July that TRYNGOLZA was "on track" for $100 million to $110 million in 2026 sales. On November 9, it lowered that target to roughly $50 million.…

Ionis Pharmaceuticals, Inc. ( IONS ) Q3 2026 Earnings Call November 9, 2026 9:00 AM EST Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Kyle Jenne - Execu…

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stock is trading at a 52-week low after the company lowered Tryngolza (olezarsen) 2026 product sales guidance.…

Ionis Pharmaceuticals NASDAQ: IONS lowered its 2026 sales forecast for TRYNGOLZA after a slower-than-expected launch in severe hypertriglyceridemia, while pushing its target for sustained positive cash flow back by a yea…

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to …

PHILADELPHIA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P. C. is investigating potential securities claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS) following…

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.61 per share a year ago.…

Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.…

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026. “In 2026, we continu…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

